Evidence map›Paper›PMID 29769597›Full record

ArticleScientific reports2018

Long-term risk for end-stage kidney disease and death in a large population-based cohort.

Emanuel Zitt, Constanze Pscheidt, Hans Concin, Reinhard Kramar, Raphael S Peter, Jan Beyersmann, Karl Lhotta, Gabriele Nagel

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Emanuel ZittDepartment of Nephrology and Dialysis, Academic Teaching Hospital Feldkirch, Feldkirch, Austria. emanuel.zitt@lkhf.at.ORCID 0000-0001-6944-6041
Constanze PscheidtAgency for Preventive and Social Medicine, Bregenz, Austria.
Hans ConcinAgency for Preventive and Social Medicine, Bregenz, Austria.
Reinhard KramarAustrian Dialysis and Transplant Registry, Rohr im Kremstal, Austria.
Raphael S PeterInstitute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.ORCID 0000-0003-4310-9500
Jan BeyersmannDepartment of Statistics, Ulm University, Ulm, Germany.
Karl LhottaDepartment of Nephrology and Dialysis, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
Gabriele NagelAgency for Preventive and Social Medicine, Bregenz, Austria.
Universität Ulm · DELandeskrankenhaus Feldkirch · ATStatistics Austria · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knowledge of metabolic risk factors for end-stage kidney disease (ESKD) in the general population is limited when considering the competing event death in risk analysis. The aim of our prospective observational study was to investigate how blood pressure and metabolic factors might influence the risks for ESKD and death before ESKD in a large Austrian population-based cohort with long-term follow-up. 177,255 participants (53.8% women; mean age 42.5 years) were recruited between 1988 and 2005 and linked to the Austrian Dialysis and Transplant Registry and the National Mortality Registry. Over a mean follow-up of 16 years 358 participants reached ESKD and 19,512 participants died. Applying fully adjusted cause-specific Cox proportional hazards models elevated fasting blood glucose, hypertension, hypertrigylceridemia and hypercholesterolemia were associated with a higher relative risk for ESKD than for death before ESKD, whereas elevated γ-glutamyltransferase was associated with an increased relative risk of death but not ESKD. Results were similar using continuous or categorical exposure variable measures in the general cohort but differed in selected high-risk populations. These findings might help improve the design of renal risk factor modification trials and kidney disease awareness and prevention programs in the general population, which may ultimately decrease the burden of ESKD.

Indexed as

AdultAustriaCause of DeathDisease ProgressionFemaleHumansKidney Failure, ChronicLongitudinal StudiesMaleMiddle AgedPrognosisProspective StudiesRegistriesRenal DialysisRisk FactorsSurvival Rate

Identifiers

PMID29769597
PMCPMC5955909
OpenAlexW2807249085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.